Immunovant CLO sells 2,877 shares for tax withholding

Immunovant, Inc.’s Chief Legal Officer Christopher Van Tuyl reported a mandated tax-related share sale.

Rhea-AI Filing Summary

Immunovant, Inc.’s Chief Legal Officer Christopher Van Tuyl reported a mandated tax-related share sale. On March 18, he disposed of 2,877 shares of common stock at $24.97 per share to cover tax withholding obligations from recently vested restricted stock units. After this transaction, he directly holds 147,053 shares. The company notes this "sell to cover" sale was required under its tax withholding policy and was not a discretionary trade.

Insider Trade Summary

Net Seller: 2,877 shares

Net Sell 1 txn

Insider Van Tuyl Christopher

Role Chief Legal Officer

Sold 2,877 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,877	$24.97	$72K

Holdings After Transaction: Common Stock — 147,053 shares (Direct)

Footnotes (1)

1. F1. On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on March 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunovant (IMVT) report for Christopher Van Tuyl?

Immunovant’s Chief Legal Officer Christopher Van Tuyl reported disposing of 2,877 common shares. The shares were sold at $24.97 each to satisfy tax withholding obligations related to vested restricted stock units, rather than as a discretionary open-market trade.

Why did Immunovant’s CLO sell 2,877 IMVT shares on March 18, 2026?

The 2,877 shares were sold to cover tax withholding obligations from vested restricted stock units. Immunovant elected to satisfy these taxes via a mandated "sell to cover" transaction, so the sale did not represent a discretionary investment decision by the executive.

How many Immunovant (IMVT) shares does Christopher Van Tuyl hold after this Form 4?

Following the tax-related sale, Christopher Van Tuyl directly holds 147,053 shares of Immunovant common stock. This figure reflects his remaining position after disposing of 2,877 shares to cover withholding taxes tied to the vesting and settlement of restricted stock units.

Were the Immunovant (IMVT) shares sold by the CLO part of vested RSUs?

Yes. A prior grant of 109,956 restricted stock units included 6,872 RSUs that vested on March 16, 2026. The 2,877 shares sold were specifically used to fund tax withholding obligations arising from the vesting and settlement of those RSUs, under the company’s policy.

Was the March 18, 2026 sale by Immunovant’s CLO a discretionary trade?

No. The company states the sale was mandated by its election to fund tax withholding through a "sell to cover" transaction. As a result, the trade was executed to meet tax obligations and did not represent a voluntary decision to reduce his Immunovant shareholdings.

What prior equity award to Immunovant’s CLO is referenced in this Form 4?

The filing references a grant of 109,956 restricted stock units on December 16, 2024, previously reported in a December 18, 2024 Form 4. Of that award, 6,872 RSUs vested on March 16, 2026, triggering the associated tax withholding that led to the share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Tuyl Christopher

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		S		2,877(1)	D	$24.97	147,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on March 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)